Radiation therapy for extrahepatic bile duct cancer: Current evidences and future perspectives

Table 2 Contemporary series of definitive radiotherapy for unresectable extrahepatic bile duct cancer

Ref.	Study period	Study design	No. of pts	EBRT (median)	Brachytherapy	Chemotherapy	Median OS (mo)
Deodata et al[44]	1991-1997	Retrospective	22	50.4 Gy	30-50 Gy (n = 12)	5-FU (95.5%)	23.01
Brunner et al[45]	1994-2001	Retrospective	25	45 Gy	10 Gy (n = 4)	FM (40%), GP (56%)	11.82
Schleicher et al[46]	1991-1999	Retrospective	30	30 Gy	24-40 Gy (n = 18)	5-FU (80%)	5.72
Takamura et al[48]	1988-1998	Retrospective	93	50 Gy	39.2 Gy3	-	122
Shin et al[49]	1986-1995	Retrospective	31	50.4 Gy	15 Gy (n = 14)	-	21%4	P = 0.015
					- (n = 17)		0%4
Yoshioka et al[50]	2000-2011	Retrospective	209	50 Gy	8-30 Gy (n = 56)	Various (57%)	31%4	P = 0.862
					- (n = 153)		40%4
Torgeson et al[42]	2004-2014	NCBD	1070	54-89 Gy	-	Various (100%)	14.5	P < 0.001
			1871	-	-		12.6
Autorino et al[47]	2002-2009	Phase 2	27	50 Gy	15-20 Gy (n = 6)	Gemcitabine (100%)	14

¹From the date of cancer diagnosis;

²From the time of radiotherapy initiation;

³mean;

⁴2-yr overall survival rate. ERRT: External beam radiotherapy; OS: Overall survival; 5-FU: 5-fluorouracil; FM: 5-FU plus mitomycin-C; GP: Gemcitabine plus cisplatin; NCDB: National Cancer Database.